Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. The company has developed the world’s most advanced health check for the health industry, offering risk detection for multiple chronic diseases from a single blood sample. Their Health Check can be scaled to entire populations at a low cost and can replace many current risk assessments. Detecting disease risks on a population level allows for effective targeting and tracking of health interventions, helping prevent the onset of chronic diseases. They operate globally with a parent company in Finland and subsidiaries in countries including Japan, the United States, Singapore, and the United Kingdom. Nightingale Health serves customers in more than 25 countries across healthcare and medical research sectors. Their technology is utilized in leading health initiatives like the UK Biobank, supported by over 600 peer-reviewed publications.

Key milestones include the 2025 Nasdaq Helsinki Main Market listing, expansions into genetics and international genomic data analysis, collaborations with major health organizations such as Kaiser Foundation and 23andMe, and the opening of laboratories in the UK and the United States. Since its founding in 2013 based on a scientific innovation of a single blood test that detects a wide variety of molecules, Nightingale Health has continuously grown and expanded globally.

The leadership team comprises experienced professionals including CEO and Founder Teemu Suna, CTO and Founder Antti Kangas, and other key officers leading commercial, scientific, and operational roles. Highlights include Chief Scientific Officer Jeffrey Barrett, PhD, and Chief Clinical Officer Charles Alessi, Dr.